Key result
Single intravenous treatment with irbesartan-NP at the time of reperfusion significantly reduced infarct size and ameliorated left ventricular remodeling in a mouse model of myocardial ischemia-reperfusion injury.
Why the study?
Does nanoparticle-mediated delivery of irbesartan reduce infarct size and left ventricular remodeling in a mouse model of myocardial ischemia-reperfusion injury?
Does nanoparticle-mediated delivery of irbesartan reduce infarct size and left ventricular remodeling in a mouse model of myocardial ischemia-reperfusion injury?
Nanoparticle-mediated delivery of irbesartan offers a novel targeted approach to reduce ischemia-reperfusion injury and adverse remodeling following acute myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Does not support clinical use; leaves open targeted irbesartan nanoparticle delivery for ischemia-reperfusion injury.
Nakano et al. (2016) studied Myocardial ischemia-reperfusion injury. Irbesartan-NP (PLGA nanoparticles incorporating irbesartan) vs. Saline, control nanoparticles, or irbesartan solution was evaluated on Infarct size 24 hours after reperfusion. Single intravenous treatment with irbesartan-NP at the time of reperfusion significantly reduced infarct size and ameliorated left ventricular remodeling in a mouse model of myocardial ischemia-reperfusion injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: